Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: A report of the results and benefits using recombinant human thyrotropin in clinical routine

Thyroid

Volumn 15, Issue 4, 2005, Pages 371-376

  Kohlfuerst, Susanne ^a   Igerc, Isabelle ^a   Lind, Peter ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN;

CONFERENCE PAPER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 18744363345     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.371     Document Type: Conference Paper

References (48)

1. Schlumberger M 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
2. Mazzaferri E 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421-427.
3. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645.
4. Mazzaferri EL, Kloos RT 2000 Using recombinant human TSH in the management of well-differentiated thyroid cancer: Current strategies and future directions. Thyroid 10:767-778.
5. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86: 619-625.
6. Toft A, Beckett G 2002 Use of recombinant thyrotropin. Lancet 359:1874-1875.
7. Robbins RJ, Tuttle RM, Sonenberg M, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869.
8. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, and Pezzino V 2001 Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 11:1025-1029.
9. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 144:5-11.
10. Dow KH, Ferrell BR, Anello C 1997 Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7:613-619.
11. Petrich T, Börner AR, Weckesser E, Soudah B, Otto D, Widjaja A, Hofmann M, Kreipe HH, Knapp WH 2001 Follow-up of thyroid cancer patients using rhTSH-preliminary results. Nuklearmedizin 40:7-14.
12. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, MaxonIII HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A Comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
13. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A 2004 Follow up of low risk patients with differentiated thyroid carcinoma: A European perspective. Eur J Endocrinol 150:105-112.
14. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
15. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, Reiners C 2003 Comparison of radioiodine biokinetics following the administration of recombinant thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Med Mol Imaging 30:1371-1377.
16. 131I. J Nucl Med 44:898-903.
17. Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio Violi MA, Cianci M, Vigneri R, Pezzino V, Squatrito S 2003 The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent diseaes and low thyroglobulin levels. Clin Endocrinol (Oxf) 58:556-561.
18. Mazzaferri EL, Massoll N 2002 Management of papillary and follicular (differentiated) thyroid cancer: New Paradigms using recombinant human thyrotropin. J Endocrinol Relat Cancer 9:227-247.
19. Wartofsky L 2002 Management of low-risk-well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583-590.
20. Braga M, Ringel MD, Cooper DS 2001 Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 86:5148-5151.
21. Schlumberger MJ, Incerti C, Reiners C 1999 The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion. J Endocrinol Invest 22:35-41.
22. Krausz Y, Uziely B, Nesher R, Chisin R, Glaser B 2001 Recombinant thyroid-stimulating hormone in differentiated thyroid cancer. J Isr Med Assoc 3:843-849.
23. Achong DM, Tenorio LE 2001 I-123 uptake by mediastinal goiter after recombinant human thyroid-stimulating hormone administration. Clin Nucl Med 26:817-819.
24. Ladenson PW, Ewertz ME, Dickey RA 2001 Pratical application of recombinant thyrotropin testing in clinical practice. Endocr Pract 7:195-201.
25. Sarkar SD, Afriyie MO, Palestro CJ 2001 Recombinant human thyroid-stimulating hormone-aided scintigraphy: Comparison of imaging at multiple times after I-131 administration. Clin Nucl.Med 26:392-395.
26. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH 2001 Effect of various doses of recombinant human thyrotropin on the thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 86:1660-1664.
27. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM 2000 Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: Case report and review of literature. Endocr Pract 6:460-464.
28. McDougall IR, Weigel RJ 2001 Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 13:39-43.
29. Schlumberger M, Ricard M, Pacini F 2000 Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 143:557-563.
30. Luster M, Reinhardt W, Korber C, Lassmann M, Haenscheid H, Michalowski U, Rendl J, Eising E, Mann K, Reiners C 2000 The use of recombinant humanTSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 23:473-475.
31. Ladenson PW 2000 Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30:98-106.
32. Pacini F, Lippi F 1999 Clinical experience with recombinant human-stimulating hormone(rhTSH): Serum thyroglobuin measurement. J Endocrinol Invest 22:25-29.
33. Reiners C, Lustre M, Lassmann M 1999 Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole body scannino with iodine-131. J Endocrinol Invest 22:17-24.
34. Baskin HJ, Atwood TM, Holcomb LP 2000 Recombinant human thyrotropin in the follow-up of patients with stage I or II differentiated thyroid carcinoma. Endocr Pract 6:430-434.
35. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, Boni G, Bodei L, Rabitti C, Molinari E, Bianchi R 2000 Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 15:211-217.
36. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87:3242-3247.
37. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Fichera A 2002 Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501.
38. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178.
39. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
40. 131I whole body scan after recombinant human TSH stimulation in the follow-up of low risk patients with differentiated thyroid cancer. The rule for neck ultrasonographie. Eur J Endocrinol 148:19-24.
41. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Cecarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
42. 131I whole body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 42:1470-1475.
43. 131I. Eur J Med Mol Imaging 29:1421-1427.
44. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, Lopez de la Torre M, Becerra A, Carreras JL 2000 Utility of fluorine-18-fluorurodeoxyglucose positron emission tomographie in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am Journal of Surgery 179:457-461.
45. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A 1994 Influence of diagnostic radioiodines on the uptake of ablativedose of iodine 131. Thyroid 4:49-54.
46. 131I irridiation in cultered thyroid epithelial cells. J Nucl Med 43:828-834.
47. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 rhTSH-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Cin Endocrinol Metab 88:3668-3673.
48. Frasoldati A, Presenti M, Gallo M, Carrogio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90-96.